Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2001

View Archived Issues

Old drugs may be new therapy for Creutzfeldt-Jakob and other prion diseases

Studies demonstrate antiatherosclerotic effects of lutein

Amsterdam Molecular Therapeutics steps up LPL gene therapy program

CV Therapeutics commences phase II clinical trial of CVT-3146

Nycomed Amersham Imaging and Affitech expand human antibody agreement

CA4P development program continues as planned

Pharmacopeia and Eos Biotechnology agree to merge

Helivax demonstrates safety, immunogenicity in phase Ib trial

Two centers added to 12-week study of Neotrofin in spinal cord injury

Enbrel shows positive results in phase II clinical study of psoriasis

Invitrogen to market lentiviral vectors from Cell Genesys

Aventis highlights pipeline progress for first half of 2001

Oral suspension formulation of Trileptal soon to be available in Europe

Potent, orally bioavailable FTase inhibitors discovered at Aventis

Pharmacia presents a potent MMP inhibitor at ACS meeting in Chicago

Novel cytokine production inhibitors highlighted at the ongoing ACS meeting

Demegen receives grant in support of P-113D development for cystic fibrosis infections

Selective epoxyketone inhibitors developed at Yale University

BMS patents compounds having unique dopaminergic and serotonergic activity

Potent and selective integrin inhibitors reported by Celltech

Bone-targeting compounds in the Ariad pipeline

NeuroSearch patents nACh receptor modulators

Research at Amgen leads to the discovery of new integrin antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.